Western blot analysis was conducted using the procedure previously described [55 (link)]. We used antibodies against Lrp5 (5731s, RRID:AB_10705602), MMP2 (87809s, RRID:AB_2800107), Runx2 (8486s, RRID:AB_10949892), Snail (3879s, RRID:AB_2255011), TGFβ (3711s, RRID:AB_2063354), cleaved caspase 3 (9661s, RRID:AB_2341188) (Cell Signaling, Danvers, MA, USA), MMP3 (sc-21732, RRID:AB_627958), MMP9 (sc-393859), cathepsin K (sc-48353, RRID:AB_2087687), NFATc1 (sc-7294, RRID:AB_2152503) (Santa Cruz, Dallas, TX, USA), Nexin (ab222754), Chemerin (ab103153, RRID:AB_10861013) (Abcam, Cambridge, MA, USA), p53 (UJ290170, Invitrogen, Carlsbad, CA, USA), TRAIL (NB500220, NOVUS, Centennial, CO, USA, RRID:AB_10003305), and β-actin (A5441, Sigma-Aldrich, Saint Louis, MO, USA, RRID:AB_476744). RNA interference was conducted using siRNA specific to Chemerin (#82104), nexin (#150176), and Lrp5 (s69315) (Thermo-Fisher, Waltham, MA 02451, USA), with a negative siRNA (Silencer Select #1, Thermo-Fisher) using the procedure previously described [56 (link)]. The overexpression of Lrp5 and p53 was achieved by transfecting Lrp5 plasmids (#115907, Addgene, Cambridge, MA, USA, RRID:Addgene_115907), and p53 plasmids (#69003, Addgene, Cambridge, MA, USA, RRID:Addgene_69003), respectively.
Free full text: Click here